The Use of Cannabis for Headache Disorders Bryson C. Lochte, Alexandre Beletsky, Nebiyou K. Samuel, Igor Grant Cannabis and Cannabinoid Research, 2017, Vol. 2, No 1., 61-71 https://doi.org/10.1089/can.2016.0033 Abstract Headache disorders are common, debilitating, and, in many cases, inadequately managed by existing treatments. Although clinical trials of cannabis for neuropathic pain have shown promising results, there has been limited research on its use, specifically for headache disorders. This review considers historical prescription practices, summarizes the existing reports on the use of cannabis for headache, and examines the preclinical literature exploring the role of exogenous and endogenous cannabinoids to alter headache pathophysiology. Currently, there is not [...]
Lire la suiteThe pharmacokinetics and the pharmacodynamics of cannabinoids Catherine J. Lucas, Peter Galettis and Jennifer Schneider British Journal of Clinical Pharmacology, 2018, 84, 2477–2482 DOI:10.1111/bcp.13710 Abstract : There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers. Cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta-9-tetrahydrocannabinol (THC), which is psychoactive, and the nonpsychoactive cannabidiol (CBD). Cannabis use is associated with both pathological and behavioural toxicity and, accordingly, is contraindicated in the context of significant psychiatric, cardiovascular, renal or hepatic illness. The pharmacokinetics of cannabinoids and the [...]
Lire la suiteBibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles. Dr Christian Sueur, GRECC, mars 2019. (2e version) ARAN A., CASSUTO H., LUBOTZKY : Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasability Study (P3.318), Neurology Genetics, 2018, 90 (15). http://n.neurology.org/content/90/15_Supplement/P3.318 ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasability Study, Journal of Autism and Developmental Disorders, 2018 Oct 31. Doi : 10.1007/s10803-018-3808-2 BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. : Oral Cannabidiol Use in Children With Auttism Spectrum Disorder to Treat Related Symptoms [...]
Lire la suiteCannabis thérapeutique : les premiers mots historiques d’Edouard Philippe, Premier ministre 6 avril 2019 jeanyvesnau Argent, Douleur, Médecine, médicament, Pharmacie, Polémique, Politique, Pouvoir, Risques (réduction des), santé publique Étiquettes : Agence France Presse https://jeanyvesnau.com/2019/04/06/cannabis-therapeutique-premiers-mots-historiques-dedouard-philippe-premier-ministre/ Bonjour Il l’a dit avec ses mots et ses mots sont ceux d’un Premier ministre. Pour la première fois le chef de gouvernement français s’est exprimé sur le « cannabis thérapeutique ». Et il l’a dit, politique oblige, lors d’un déplacement officiel dans le département périphérique de la Creuse, préfecture Guéret, une seule sous-préfecture : Aubusson. La Creuse, département pauvre, qui nourrit depuis plusieurs mois un projet de culture de cannabis à visée thérapeutique. Un [...]
Lire la suiteEdouard Philippe estime qu'il serait "absurde" de ne pas étudier une autorisation du cannabis thérapeutique France Info , 5 avril 2019 En déplacement dans la Creuse, qui envisage la création d'une filière de production, le Premier ministre s'est dit favorable "à expérimenter (...) de façon très encadrée". La France s'ouvrira-t-elle un jour à l'utilisation du cannabis thérapeutique ? Edouard Philippe a déclaré, vendredi 5 avril, qu'il serait "absurde" de s'interdire d'étudier cette possibilité. Le Premier ministre était en déplacement dans la Creuse, un département où la culture du cannabis à des fins médicales est envisagée comme un moyen de développer l'emploi et l'économie. "Il y a beaucoup de [...]
Lire la suiteThe Association between Cannabis Product Characteristics and Symptom Relief Sarah S. STITH, Jacob M. VIGIL, Franco BROCKELMAN, Keenan KEELING, Branden HALL Scientific Reports - Nature, 2019, 9, 2712. Published online 2019 Feb 25. doi: 10.1038/s41598-019-39462-1 PMCID: PMC6389973 PMID: 30804402 Abstract Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo. Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, ReleafApp to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis [...]
Lire la suiteClinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]
Lire la suiteA protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation Nadia SOLOWIJ, Samantha J. BROYD, Hendrika H. Van HELL, Arno HAZEKAMP BMC Pharmacol Toxicol, 2014, 15, 58 Published online 2014 Oct 16. doi: 10.1186/2050-6511-15-58 PMCID: PMC4274767 PMID: 25319497 Abstract Background Significant interest has emerged in the therapeutic and interactive effects of different cannabinoids. Cannabidiol (CBD) has been shown to have anxiolytic and antipsychotic effects with high doses administered orally. We report a series of studies conducted to determine the vaporisation efficiency of high doses of CBD, alone and in combination with ∆9-tetrahydrocannabinol (THC), to achieve faster onset effects in experimental and clinical [...]
Lire la suiteProspects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Tomasz DZIERZANOWSKI Cancers (Basel), 2019, 11, 2 Abstract There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was confirmed in [...]
Lire la suiteCannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]
Lire la suite